Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1837]
News [4190]
Articles [374]
Editorials [10]
Conferences [105]
elearning [28]
CDK 4/6 inhibitors: Management of side effects
Dr Alison Jones - The LOC, London, UK
CDK 4/6 inhibitors: Management of side effects ( Dr Alison Jones - The LOC, London, UK )
15 Nov 2016
Survivorship care planning for post-menopausal breast cancer patients in Ireland
Elizabeth Meade - Ireland's Health Service, Dublin, Ireland
Survivorship care planning for post-menopausal breast cancer patients in Ireland ( Elizabeth Meade - Ireland's Health Service, Dublin, Ireland )
8 Nov 2016
CDK clinical trial results, benefit, side effects and costs
Dr Pierfranco Conte - Instituto Oncologico Veneto, Padua, Italy
CDK clinical trial results, benefit, side effects and costs ( Dr Pierfranco Conte - Instituto Oncologico Veneto, Padua, Italy )
26 Oct 2016
Extending indication of CDK 4/6 inhibitors in the adjuvant and neoadjuvant...
Dr Sara Hurvitz - UCLA Medical Center, Santa Monica, USA
Extending indication of CDK 4/6 inhibitors in the adjuvant and neoadjuvant setting ( Dr Sara Hurvitz - UCLA Medical Center, Santa Monica, USA )
26 Oct 2016
Coming of age for CDK 4/6 inhibitors: Interactive session and close
Dr Giuesppe Curigliano - European Institute of Oncology, Milan, Italy
Coming of age for CDK 4/6 inhibitors: Interactive session and close ( Dr Giuesppe Curigliano - European Institute of Oncology, Milan, Italy )
26 Oct 2016
Editor's ESMO 2016 roundup
Prof Gordon McVie - Editor in Chief, ecancer
Editor's ESMO 2016 roundup ( Prof Gordon McVie - Editor in Chief, ecancer )
24 Oct 2016
CDK4/6 inhibition: PALOMA2 versus MONALEESA2
Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria
CDK4/6 inhibition: PALOMA2 versus MONALEESA2 ( Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria )
17 Oct 2016
CDK4/6 inhibitors for metastatic breast cancer
Dr Giuseppe Curigliano - European Institute of Oncology, Milan, Italy
CDK4/6 inhibitors for metastatic breast cancer ( Dr Giuseppe Curigliano - European Institute of Oncology, Milan, Italy )
14 Oct 2016
Who should receive combination therapy for ER positive breast cancer?
Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria
Who should receive combination therapy for ER positive breast cancer? ( Dr Michael Gnant - Medizinischen Universität Wien, Vienna, Austria )
12 Oct 2016
ESMO 2016 conference highlights
Dr Bishal Gyawali - Nagoya University, Nagoya, Japan
ESMO 2016 conference highlights ( Dr Bishal Gyawali - Nagoya University, Nagoya, Japan )
12 Oct 2016
Lurbinectedin in PARP resistant breast cancer
Dr Cristina Cruz - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Lurbinectedin in PARP resistant breast cancer ( Dr Cristina Cruz - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
10 Oct 2016
Lurbinectedin in BRCA 1/2 breast cancer
Dr Judith Balmaña - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Lurbinectedin in BRCA 1/2 breast cancer ( Dr Judith Balmaña - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )
10 Oct 2016

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation